Alnylam Pharmaceuticals

ALNY · NASDAQ

$230.71−$2.58 (−1.11%)TodayMarket closed ·
Prev close $233.29

ALNY analyst rating

BuyConsensus of 23 analysts over the last 12 months. 83% rate it a buy.
  • Strong buy1
  • Buy18
  • Hold4
  • Underperform0
  • Sell0

12-month price target · 30 analysts

Average $378.84 (+64.2% upside)

Low
$238.36
Now
$230.71
High
$594.30

Upgrades and downgrades

The latest rating actions, newest first

ALNY analyst upgrades, downgrades and rating actions
FirmDateActionRating
UBSOct 15, 2026InitiatesBuy
CitigroupOct 14, 2026MaintainsBuy
Wells FargoOct 14, 2026MaintainsEqual-Weight
RBC CapitalOct 8, 2026MaintainsOutperform
JP MorganSep 30, 2026MaintainsOverweight
HC Wainwright & Co.Sep 21, 2026MaintainsBuy
JefferiesSep 8, 2026MaintainsHold
HC Wainwright & Co.Sep 2, 2026MaintainsBuy
BMO CapitalAug 19, 2026InitiatesOutperform
Wells FargoAug 14, 2026MaintainsEqual-Weight

The case for and against

Updated Oct 14, 2026

Bull case

Alnylam Pharmaceuticals is positioned as a differentiated RNAi leader with a durable commercial base in ATTR-CM, supported by AMVUTTRA’s broad label, the underpenetrated nature of a market Alnylam estimates at ~200,000 U.S. patients and ~500,000 globally, and a cardiology channel that is already maturing through buy-and-bill access. Its outlook is further strengthened by a broadening pipeline and partner assets, including zilebesiran with Roche and LEQVIO’s validation of prevalent-disease siRNA commercialization, while management’s view that ZENITH could support a 15% to 20% MACE reduction underscores meaningful second-franchise potential in cardiovascular disease. Even with net price normalization pressure, the company’s demand trends, improving prescriber and payer receptivity, and nucresiran’s favorable economics support expanding revenues, with the TTR franchise modeled to exceed $20.5 billion in peak annual revenue by 2040.

Bear case

Alnylam Pharmaceuticals is constrained by a valuation that depends heavily on late-2020s RNAi revenue build-out and several high-risk pipeline bets, leaving only a modest present value despite 100% success assumptions for AMVUTTRA, nucresiran, and QFITLIA. Its outlook is further pressured by meaningful execution and legal overhangs, including the U.S. Attorney’s Office subpoena on government price reporting, which management expects may create significant expense and could hurt gross-to-net and profitability. In hypertension, zilebesiran’s path is especially uncertain because broader use of aldosterone synthase inhibitors may compress efficacy separation and event rates, while safety questions persist around hypotension and hyperkalemia, with 889 patients exposed and hyperkalemia at 2.7% versus 0.9% on placebo.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.